Fig. 1From: A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary diseaseSubject disposition*Due to metastatic lung cancer, cardiopulmonary failure and cardiac failure. †Due to pneumonia, metastatic neoplasm, necrotising pancreatitis, cerebral haemorrhage, dyspnoea and pulmonary embolismBack to article page